233. Wolfram syndrome Clinical trials / Disease details
Clinical trials : 11 / Drugs : 17 - (DrugBank : 8) / Drug target genes : 12 - Drug target pathways : 41
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05659368 (ClinicalTrials.gov) | January 2023 | 5/12/2022 | Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1 | Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1 | Wolfram Syndrome | Drug: Tirzepatide | Ospedale San Raffaele | NULL | Not yet recruiting | 5 Years | N/A | All | 10 | Phase 2 | NULL |